Can we meet global challenges for elimination of Hepatitis B Virus infection by 2030? Vaccine-mediated immunity in a South African cohort and a model of transmission and prevention

Anna McNaughton[1*], José Lourenço[2*], Louise Hattingh[3*], Emily Adland[4], Samantha Daniels[3], Anriette Van Zyl[3], Connie S Akiror[5], Susan Wareing[6], Katie Jeffery[6], Azim Ansari[1], Paul Klenerman[1,6], Philip J R Goulder[4], Sunetra Gupta[2], Pieter Jooste[3], Philippa C Matthews[1,6*]

* These three authors contributed equally to the work presented here

[1] Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK

[2] Department of Zoology, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK

[3] Department of Paediatrics, Kimberley Hospital, Kimberley, 8300, South Africa

[4] Department of Paediatrics, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK

[5] Global Healthcare Public Foundation, Makindu Lane, Kololo, Kampala, Uganda

[6] Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK

* Corresponding author: philippa.matthews@ndm.ox.ac.uk

RUNNING HEAD: HBV vaccine responses and model of timescale to elimination

KEYWORDS: hepatitis b virus; HBV; HIV; co-infection; epidemiology; Africa; South Africa; children; paediatrics; antibodies; vaccine; immunisation; elimination; transmission; dynamics; model; simulation; vertical transmission; PMTCT; number needed to vaccinate; sustainable development goals; public health

ABBREVIATIONS

- 3TC - Lamivudine
- Anti-HBc – antibody to hepatitis B core antigen (antibody mediated by exposure to infection)
- Anti-HBe – antibody to hepatitis B envelope antigen
- Anti-HBs – antibody to hepatitis B surface antigen (vaccine-mediated antibody)
- ART – anti-retroviral therapy
- COSAC – coinfection in South African children
- EPI – Expanded Programme on Immunisation
- FTC - Entecavir
- HBV – hepatitis B virus
- HBcAg – Hepatitis B core antigen
- HBeAg – Hepatitis B envelope antigen
- HBsAg – Hepatitis B surface antigen
- HIV – human immunodeficiency virus (type 1)
- KReC – Kimberley Respiratory Cohort
- PMTCT – prevention of mother to child transmission
- RTHB – Road to Health Book
- TDF – Tenofovir
- UN – United Nations
- WHO – World Health Organisation

ABSTRACT

Background: Sustainable Development Goals and the World Health Organisation (WHO) Global health sector strategy on viral hepatitis have set a challenge for the elimination of hepatitis B virus (HBV) infection as a public health concern by the year 2030. Based on current estimates of 250 million individuals with chronic infection, an intensive scale-up of interventions will be required. We set out to characterise the epidemiology of HBV infection and the prevalence of vaccine-mediated protection in a cohort of South African children, and used these data, alongside parameters from the published literature, to inform a model of HBV transmission and prevention. This has allowed us to develop evidence-based insights into the extent to which scaling up vaccination and prevention of mother-to-child transmission (PMTCT) might ultimately contribute to HBV elimination, and to assess the extent to which the targets for 2030 are realistic.

Methods and findings: We studied a cohort of 310 children (136 HIV-positive; 174 HIV-negative) aged 6-60 months in Kimberley, South Africa. Less than 1% of children in this setting were HBV infected (HBsAg positive). A vaccine-mediated antibody (anti-HBs) titre ≥10 mIU/ml was present in 238/310 children (77%). Anti-HBs titres were higher in HIV-negative children and in younger children ($p<0.0001$ in each case). Using these data, together with estimates of HBV transmission and epidemiology derived from the wider literature, we developed a model of HBV infection dynamics. We used this model to investigate the influence of prevention strategies, focusing on vaccination and PMTCT. Current vaccination efforts can be predicted to reduce population prevalence by ~20% in the first 25 years, but can bring the prevalence of HBV e-antigen (HBeAg)-positive chronic carriers down by ~40% in the same time period. We show likely additional benefit in providing catch-up vaccination in the short-term, but little long-term difference. Combining neonatal vaccination with robust PMTCT is the most effective population-level strategy to secure short-term impact, but coverage of both interventions needs to be high. Thus with strategies and resources already available, significant, positive public health impact is possible, although time to HBV elimination is likely to be substantially longer than that proposed by current goals.

Conclusions: At the level of an individual cohort, these data reflect the substantial overall success of HBV immunisation, with <1% of children now becoming infected with HBV in an endemic setting. However, we go on to demonstrate that to move towards the target of elimination, major improvements in vaccination deployment and coverage are required, and enhanced efforts in PMTCT. Realistic targets, rather than focusing on a complete elimination of the public health threat posed by HBV by the year 2030, may be better aiming for a substantial reduction in prevalence, which will come about through vaccination, PMTCT, and reduction of HBeAg-positive carriage. The magnitude of the elimination challenge, and the long time periods of sustained investment that will be required, underline the crucial importance of parallel investment into diagnostics, advocacy, policy, education and ongoing research into HBV cure strategies.

INTRODUCTION

The World Health Organisation (WHO) and United Nations (UN) Sustainable Development Goals have set out targets for the elimination of viral hepatitis as a major public health threat by 2030 (1,2). The magnitude of this challenge becomes apparent on reviewing the burden of mortality and morbidity attributed to these infections: overall, hepatitis viruses are responsible for an estimated 1.4 million deaths annually. Of these, 47% are directly attributable to hepatitis B virus (HBV) (1), which is currently estimated to be responsible for chronic infection in 240-260 million individuals worldwide (3). The highest prevalence of HBV infection, frequently >8%, is reported in Africa and South East Asia (4), but African populations are under-represented in the current literature (5).

In South Africa, HBV is endemic: the estimated prevalence among adults is 6-11% (4,6,7), with a disproportionately higher prevalence occurring in rural regions (8,9). Conventional parenteral transmission routes are well recognised, but a substantial proportion of infections in South Africa have traditionally been attributed to horizontal transmission within households during early childhood (10). In a recent study in Kimberley, we demonstrated cases of HBV infection among children with HIV (11), despite the inclusion of the HBV vaccination in routine childhood immunisation programmes in South Africa since 1995 (10).

This vaccine, a safe and affordable recombinant surface antigen protein, has been available for over two decades (12,13), and is highly efficacious, generating immunity to HBV in >90% of immunocompetent individuals after a primary course of three doses (12,14,15). Since the mid-1990s, the WHO has encouraged universal coverage of the HBV vaccine through its Expanded Programme on Immunisation (EPI) (16) and the majority of countries now offer three doses of HBV vaccination in infancy. Antenatal screening for HBV, to reduce the risk of vertical transmission, is also advocated by the WHO (17). High maternal HBV viral loads and HBV envelope antigen (HBeAg) positivity are risk factors for transmission, and the administration of HBV immune globulin ('HBIg') immediately after birth, together with vaccination, is recommended for this group, and has been demonstrated to reduce the risk of vertical transmission to ≤3% (18). Despite the availability of interventions for prevention of mother to child transmission (PMTCT), in many regions of the world antenatal screening for HBV is not routinely offered (19,20).

EPI guidelines recommend universal administration of the HBV vaccine, with advice being to provide the primary dose in the first day of life (3,21). However, there are several challenges to the success of this strategy. In South Africa, the first dose is conventionally delayed until age 6 weeks with subsequent doses at 10 and 14 weeks, leaving a window during which

vertical transmission can occur peripartum or in the early weeks of life (22). Coverage of the third vaccine dose is difficult to ascertain with confidence; estimates for coverage in the first year of life range from 56-97% (10). South Africa's high HIV prevalence (estimated 12.7% (23)) poses a further challenge to the success of national HBV initiatives, as being HIV positive can increase the risk of peri-partum transmission of HBV, and the HBV vaccine has been demonstrated to have reduced efficacy in HIV positive individuals (24–27).

Vaccine modelling studies, which include 'number needed to vaccinate' (NNV) approaches, can be used to inform and advise on intervention strategies and to develop cost-benefit analyses for vaccination programmes (28). Such models are based on parameters that include vaccine efficacy, and the incidence, prevalence and transmission rates of a given infection (29). A recent modelling study has considered the contribution of vaccination towards the global elimination of HBV (30), but the broad approach and inclusion of vaccination as one of many potential interventions makes it difficult to single out the role and influence of immunisation. Although the HBV vaccine is one of the most robust and widely used immunisations, to the best of our knowledge there is no specific HBV vaccine model in the published literature.

In order to investigate HBV vaccine coverage and vaccine-mediated immunity in South Africa, we set out to investigate HBV sero-epidemiology. We then used insights gained from these data gathered in one specific site, together with a detailed panel of other parameters that are reported in the existing literature, to develop a model that illustrates HBV dynamics and transmission. The model allows us to quantify the individual impact of different interventions in a way that would never be possible in a clinical study. This underpins a better understanding of specific ways in which prevention strategies can be developed and improved, informs wise deployment of limited resources, and provides insights that inform our approach to the challenges of measuring progress. In summary, this work first provides a detailed picture of the extent to which existing prevention measures are already having an impact (clinical cohort study), and then uses this as a foundation to quantify (through a mathematical model) how enhancements in vaccination and PMTCT strategies could improve our chances of meeting targets for elimination over time.

MATERIALS AND METHODS

Ethics Approval

Ethics approval for the study was obtained from the Ethics Committee of the Faculty of Health Science, University of the Free State, Bloemfontein, South Africa (HIV Study Ref:

ETOVS Nr 08/09 and COSAC Study Ref: ECUFS NR 80/2014). Written consent for enrolment into the study was obtained from the child's parent or guardian.

Study cohorts

Children were recruited as part of the Co-infection in South-African Children (COSAC) study, in Kimberley, South Africa, as previously described (11,31). We set the lower age limit of recruitment as 6 months in order to limit the detection of maternal anti-HBs in younger infants, and the upper limit at 60 months in order to optimise the capture of hand-held vaccine records (Road to Health Book, RTHB) carried by children aged under 5. These children were recruited from two sources:

i. HIV-negative participants (n=174), recruited through the Kimberley Respiratory Cohort (KReC) as previously described (31). These children were admitted to hospital with a clinical diagnosis of respiratory tract infection between July 2014 and August 2016. The majority of KReC children were routinely HIV-tested as a component of their clinical assessment, and were confirmed HIV-negative in 163 cases (93.7%). A further 11 children did not have an HIV test result recorded, but were assumed to be HIV-negative for the analysis based on the clinical data that were available at the time of admission to hospital.

ii. HIV-positive children (n=136) recruited primarily from HIV outpatient clinics, (recruited between September 2009 and July 2016). This includes five children who were recruited into the KReC study but subsequently tested HIV-positive. For HIV-positive children, we recorded date of commencement of ART (anti-retroviral therapy), CD4+ T cell count, CD4+ T cell percentage, and HIV RNA viral load, when these data were available. We recorded these information using the time point closest to the sample that was analysed for HBV serology.

In order to study the influence of age on vaccine-mediated responses, we also collected data from a third group of older HIV-positive children (age >60 months, range 64-193 months, n=92) as previously described (11,31). Where possible, we recorded the number of HBV vaccine doses received based on the RTHB. At the time of undertaking this study, children were immunised with three doses of a monovalent HBV vaccine (Biovac Paed). The characteristics of the cohorts are summarised in table 1 and all metadata can be found in Suppl. data 1.

Table 1: Characteristics of three paediatric study cohorts, comprising 402 children, recruited from Kimberley Hospital, South Africa.

Cohort	HIV negative; KReC (age ≤60 months)	HIV positive (age ≤60 months)	HIV positive (age >60 months)
Number of subjects	174	136	92
Age range in months	8-58	6-60	64-193
Median age in months (IQR)	18 (12-26)	29 (18-40)	137 (122-154)
Sex (% male)	55.4	44.9	45.6

KReC = Kimberley Respiratory Cohort. IQR = interquartile range.

Laboratory assessment of HBV status

Testing for Hepatitis B serum markers and DNA was performed as previously described; for HIV-positive children this is in keeping with recent implementation of HBV screening in Kimberley (11). Briefly, HBsAg testing was carried out in Kimberley Hospital, South Africa using the Magnetic parcel chemiluminometric immunoassay (MPCI; Advia Centaur platform). Confirmatory HBsAg testing was carried out by the UKAS accredited clinical microbiology laboratory at Oxford University Hospitals (OUH) NHS Foundation Trust, Oxford, UK (Architect i2000). For all samples, anti-HBs and anti-HBc testing were carried out by the OUH laboratory (Architect i2000). Limit of detection of the anti-HBs assay was 10 mIU/ml.

Setting a threshold for vaccine mediated immunity

In practice, a threshold for vaccine-mediated immunity is difficult to define, and studies variably quote anti-HBs titres of ≥10 mIU/ml or ≥100 mIU/ml as a correlate of protection. UK recommendations for testing HBV immunity often rely on the more stringent criterion of an anti-HBs titre of ≥100 mIU/ml (32). However, early vaccine studies have highlighted that a titre of ≥10 mIU/ml is likely to be a clinically relevant threshold for protection; a study of children in The Gambia showed that children who attained an anti-HBs titre of ≥10 mIU/ml were most likely to be immune (33), and another study demonstrated increased risk of infection when antibody titres fell <10 mIU/ml (34). Due to the varying use of different thresholds, we have presented our results pertaining to both thresholds of ≥10 mIU/ml and ≥100 mIU/ml.

Statistical analysis

Data from the cohort was analysed using GraphPad Prism v.7.0. We determined significant differences between sub-sets within the cohort using Mann-Whitney U tests for non-parametric data, Fisher's exact test for categorical variables and correlation between data points was assessed using Spearman's correlation coefficient. To assess the impact of

multiple variables, we used multivariate logistic regression analysis (35) using the Statistics add-on tool in Google Sheets (https://www.google.co.uk/sheets/about/).

Mathematical model of HBV transmission and prevention

A mathematical model was developed using ordinary differential equations (ODE) and is shown in Fig 1. Parameterization of transmission and prevention was based both on our South African paediatric cohort and current literature estimates. Mid-year population estimates from 2016 published by Statistics South Africa (23) were used to underpin assumptions about life expectancy, fertility rate and infant mortality. The details and sources of these parameters can be found in Table 2.

Table 2: List of parameters used to inform a model of HBV transmission

Model symbol	Description	Value	Reference
α	demographic transition of children *(Sc)* into older ages *(Sa)*	fitted	$
□	demographic transition of infants *(Si)* into children *(Sc)*	fitted	$
ρ	$1/\rho$ = infectious period of chronic *HBeAg-*	fitted	$
θ	rate of seroconversion from *HBeAg+* to *HBeAg-*	fitted	$
β	transmission rate of chronic *HBeAg-*	fitted	$
β_m	transmission rate of chronic *HBeAg+* and acute infections *(I)*	10β	(24)
A_1	frequency of vertical transmission from *HBeAg+* mothers	0.75	(18)
A_2	frequency of vertical transmission from *HBeAg-* mothers	0.25	(18)
μ	$1/\mu$ = lifespan; μ = mortality rate of general population	59 yrs (2011)	(23)
μ'	$1/\mu'$ = lifespan; μ' = mortality rate of chronic *HBeAg+*;	50 yrs	*
σ	$1/\sigma$ = infectious period of acute infections *(I)*	0.5 yrs	(36)
γ	infant's risk for acute infection	0.95	(37)
ε	children's risk for acute infection	0.40	(37)
ψ	older ages' risk for acute infection	0.15	(37)
v_n	vaccine efficacy in susceptible infants	0.95	(12)
v_c	vaccine efficacy in susceptible children	0.95	v_n
v_a	vaccine efficacy in susceptible adults	0.95	v_n
v_{C+}	vaccine efficacy in newborns of chronic *HBeAg+* mothers	0.83	(30)
v_{C-}	vaccine efficacy in newborns of chronic *HBeAg-* mothers	0.95	(38)
δ_n	proportion vaccinated at point of entry of infants	variable	**
δ_a	proportion vaccinated at point of entry of older ages	variable	**

κ_i	proportion of infants vaccinated in catch-up	variable	**
κ_c	proportion of children vaccinated in catch-up	variable	**
κ_a	proportion of older ages vaccinated in catch-up	variable	**
ζ	reduction in vertical transmission due to intervention (PMTCT)	variable	**

($) Fitted by the Bayesian MCMC approach (see Supplementary Data File 2 for full details).
(*) Assumed parameters: sensitivity analysis is presented in supplementary material.
(**) Variable parameters: used for dynamic projections of intervention (see Results Section).

We consider the population grouped into epidemiologically relevant states as follows:

- ***Susceptible*** (S_i, S_c, S_a): sub-divided into three age groups *i, c,* and *a*, representing *infants* (<1 yr of age, designated S_i), *children* (age 1-6 yrs, designated S_c) and *older children and adults* (>6 years of age, designated S_a), respectively.
- ***Carriers*** (I, C-, C+): sub-divided into three groups represented as *acute infections* (I), chronic e-antigen positive (*HBeAg+,* designated C+) and chronic e-antigen negative (*HBeAg-*, designated C-).
- ***Recovered*** (R); individuals who have been infected but cleared, rendering them immune.
- ***Vaccinated*** (V); individuals who have received a full vaccine schedule and are assumed to have protective titres of vaccine-mediated anti-HBs.

Depending on age of infection, individuals can either sustain an acute infection (I) or become chronic carriers (C), as represented by the age-specific parameters γ, ψ, ε for S_i, S_c and S_a respectively. Chronic carriers were assumed to be initially HBeAg+ (C+), but could convert to HBeAg- (C-) at rate θ, and eventually clear infection at a rate ρ. Depending on the infection status of mothers, individuals could be born susceptible (represented by an input of Z into the S_i class) or be infected at birth (represented by an input of W into the C+ class). Population size was taken to be constant with equal births (b) and deaths (μ), and with HBeAg+ individuals (C+) having a shorter lifespan (1/μ') than the rest of the population due to severe manifestations of infection. Acutely infected individuals (I) were assumed to enter a recovered state (R) at a rate σ.

Transmission rates of carriers (β, β_m) are linked to viraemia level, with HBeAg+ (C+) and acute infections (I) sharing similar rates (β_m) and HBeAg- (C-) a lower rate (β). We assumed that acute (I) and HBeAg+ carriers (C+) had a higher transmission potential than acute and HBeAg- carriers: since the infectious period of HBeAg positive chronic is orders of

magnitude longer than of acute infections, their contribution to overall transmission both at the levels of the individual and population is much higher. A Bayesian statistical method is used to estimate transmission potential based on population HBV prevalence. It is therefore expected that the obtained distribution for transmission potential indirectly takes into account that acute infections will not be highly infectious for the entire duration of infection (that is, the estimated distribution of the transmission potential is expected to approximate a mean of potential for the entire period of infection).

Intervention strategies were considered in the model in the form of reductions in vertical transmission (PMTCT, affecting W and Z), and routine and catch-up vaccination (moving individuals to class V). Routine vaccination could take place at birth (with a proportion Z' entering class V) or effectively within the older population (as a proportion V_a of those leaving S_c entering class V, affecting individuals >6 yrs of age). Catch-up vaccination was modelled by moving a proportion of susceptible individuals in every age class into the vaccinated class in a single time event (not shown in diagram, described in detail in supplementary data file 2).

The modelling approach was subdivided into three main steps: (i) fitting to demographic and (ii) transmission backgrounds, followed by the (iii) simulation of single or combined interventions. In the first two steps we effectively fit unknown model parameters (a, c, β, ρ, θ) to population-based observations using a Bayesian Markov-Chain Monte-Carlo (MCMC) approach. After obtaining posteriors for these parameters (i, ii), we set them to the obtained medians before numerically simulating interventions (iii). Full ODE model details, fitting approach, MCMC output, as well as other results and sensitivity experiments are presented in supplementary data file 2.

RESULTS

Serological evidence of exposure to HBV infection

Evidence of current infection with HBV, determined by the detection of HBsAg, was observed in three children (0.8% of the cohort; Table 3). None of these three children attended with a written vaccination record (RTHB). Anti-HBc was detected in 0.8% subjects (n=3), one of whom was also HBsAg positive. The other two participants were HBsAg negative, indicating previous exposure to HBV infection and likely viral clearance in these subjects.

Table 3: Detailed information and serological profiles of five children from Kimberley, South Africa, with serological evidence of current or previous infection with HBV (based on positive HBsAg (n=3) or anti-HBc (n=2))

Subject	K306	K405	KReC51	KReC151	K093
Cohort	HIV-positive age ≤60 months	HIV positive age ≤60 months	KReC	KReC	HIV positive age >60 months
Sex	F	F	F	M	F
Age (months) at time of sampling	18	37	20	15	118
HIV infection	Positive	Positive	Negative	Negative	Positive
ART[a] (if HIV positive)	Yes	Yes	n/a	n/a	No
Number of doses of HBV vaccine	NK	NK	NK	3	NK
HBsAg result[b]	Detected	Detected	Detected	Not detected	Not detected
Anti-HBc result[c]	Not detected	Not detected	Detected	Detected	Detected
HBeAg result[d]	Not done	Not done	Detected	Not done	Not done
Anti-HBs result[e]	Not detected	Not detected	Not detected	Detected	Not detected
Interpretation	Active infection	Active infection	Active infection	Immunised, infected and cleared	Infected and cleared

[a]ART indicates the participant was receiving anti-retroviral therapy to treat HIV infection; [b]Hepatitis B surface antigen test; [c]Hepatitis B core antibody test; [d]Hepatitis B envelope antigen test; [e]Hepatitis B surface antibody test (vaccine mediated response). KReC = Kimberley Respiratory Cohort. n/a = not applicable.

The prevalence of HBsAg is much higher in adults in comparable study populations; in a previous study, we described HBV epidemiology in a cohort of antenatal women, and mothers attending paediatric clinics with their children in Durban and Kimberley (7). Among these adults, HBsAg prevalence was 9.5% (55/579), and the rate of HBeAg-positivity was 28% (14/50) (7).

Documented evidence of vaccination and serological evidence of immunity to HBV in children aged ≤60 months

We were able to collect written documented evidence of immunisations from the RTHB in 90.8% HIV negative (KReC) subjects but only from 6.3% of HIV positive subjects. This means that in the absence of a detectable anti-HBs titre, we cannot reliably distinguish children who are immunised but fail to mount an antibody response from children who are unimmunised. Among children with an RTHB record, 81.3% of HIV-negative and 100% of HIV-positive subjects were recorded as having received three primary doses of the HBV vaccine as stipulated by the EPI.

Across the whole cohort age 6-60 months, 238/310 children (77%) had an anti-HBs titre ≥10 mIU/ml suggesting some degree of vaccine-mediated immunity. The median anti-HBs titre in HIV-negative participants was significantly higher than among HIV-positive children (196 mIU/ml, vs. 11 mIU/ml, respectively, p<0.0001) (Fig 2A). No detectable anti-HBs titre was detected for 3.4% of HIV-negative individuals, vs. 47.8% of HIV-positive subjects (p<0.0001). Irrespective of the antibody titre used as a threshold for immunity, anti-HBs was higher in HIV-negative compared to HIV-positive children (Fig 2B, C). We found no significant difference in the anti-HBs titres between male and female participants, either with or without HIV infection (p=0.49 and 0.31 respectively).

Waning of vaccine response with age

In order to explore the influence of age on titres of vaccine-mediated immunity, we compared the ages of children who achieved anti-HBs ≥100mIU/ml vs those who did not reach this threshold, considering HIV-positive and HIV-negative groups separately. Among HIV-positive children, those with protective antibody titres were significantly younger than those not reaching this threshold (median age 17 months vs. 31 months, p=0.0008; Fig 3A). No such difference was observed within the HIV-negative group (Fig 3B). Using a threshold of ≥10mIU/ml, no significant differences were observed in the anti-HBs responses of either the HIV-positive or the HIV-negative groups (p=0.17 and 4.48 respectively). To expand our view of the HIV-positive group, we also added analysis of an older cohort (92 children aged >60 months), and demonstrated that anti-HBs titres were significantly lower in this older group (p<0.0001), with only 2/92 subjects (2.2%) achieving a detectable anti-HBs titre of ≥10mIU/ml (Fig 3C).

Anti-HBs titres waned significantly with age up to age 60 months in HIV-positive children (Fig 3D; p=0.004). No correlation was identified in the HIV-negative cohort (p=0.07, R^2=0.02), although with median anti-HBs titres declined from 336.1 mIU/ml (IQR 55.3-953.6 mIU/ml) in subjects ≤12 months to 197.1 mIU/ml (IQR 67.9-448.5 mIU/ml) in those >36 months (Fig 3E). Although the numbers of children in this cohort are small, and we did not collect

longitudinal data, these results support previous literature reports that HBV vaccine-mediated immunity wanes over time (39,40).

Stratification of vaccine responses by anti-retroviral therapy (ART) among HIV-positive children

For children aged 6-60 months, we recorded whether or not study participants were treated with ART; this information was available for 79% of subjects. Among these, 71% of HIV-positive study participants were known to be receiving anti-retroviral therapy (ART) at the time of testing for anti-HBs. These children had been treated with ART for varying lengths of time (median 20 months; IQR 6-33 months).

We compared anti-HBs titres of subjects being treated with ART compared to those not currently receiving ART and found no significant difference (p=0.72; 76 children on ART, median anti-HBs 13.3 mIU/ml and 31 children not on ART, median anti-HBs 14.1 mIU/ml). There was also no difference between anti-HBs titres of children on ART for ≤12 months compared with those treated for >12 months (p=0.50). We did not examine the effect of ART on anti-HBs titres in children >60 months old due to the low numbers of subjects in this group with a detectable anti-HBs titre (n=2).

Multivariate analysis

In a multivariate analysis, two factors were identified as predictive of a protective anti-HBs titre: age <24 months and HIV-negative status (Table 4).

Table 4: Multivariate analysis to identify factors associated with anti-HBs titre ≥100mIU/ml among HIV-positive and HIV-negative children aged 6-60 months from Kimberley, South Africa. Percentages shown represent the proportion of the entire cohort (n=310) who fall into the listed category. Row totals add up to less than 310 as a result for missing data points for some children.

Characteristic	Anti-HBs titre <100 mIU/ml		Anti-HBs titre ≥100 mIU/ml		P-value
	n=	%	n=	%	
Age <24 months	66	39.0	100	71.1	
≥24 months	103	61.0	41	28.9	0.005
Sex (Male)	84	50.0	71	50.0	
(Female)	84	50.0	70	50.0	0.276
HIV (negative)	56	31.9	118	84.5	

(positive)	113	68.1	23	15.5	< 0.0001

Among HIV-positive children age 6-60 months, CD4+ T-cell counts and HIV viral load were available for 83% of participants (suppl. data 1). We included age, sex, CD4+ T-cell counts, CD4+ T-cell proportion and HIV viral load in a multivariate analysis for protective anti-HBs responses (Table 5). In this model, age <24 months and HIV viral load ≤2.0 $\log_{10}$ were found to be predictors of an anti-HBs titre of ≥100 mIU/ml. Multivariate analysis using the lower anti-HBs titre of ≥10mIU/ml identified only HIV-negative status as a significant association.

Table 5: Multivariate analysis for factors associated with anti-HBs titre ≥100mIU/ml in HIV-positive children age 6-60 months from Kimberley, South Africa. Percentages shown represent the proportion of the entire cohort (n=136) who fall into the listed category. Row totals add up to less than 136 as a result for missing data points for some children.

Characteristic	Proportion of group with anti-HBs titre <100 mIU/ml		Proportion of group with anti-HBs titre ≥100 mIU/ml		P-value
	n=	%	n=	%	
Age (<24 months)	28	24.8	16	69.6	
(≥24 months)	85	75.2	7	30.4	0.048
Sex (Male)	52	47.7	6	30.0	
(Female)	57	52.3	14	70.0	0.432
Treatment (on ART)	63	65.6	15	75.0	
(not on ART)	33	34.4	5	25.0	0.568
CD4+ count (<1000)	36	39.1	5	33.3	
(≥1000)	56	60.9	10	66.7	0.954
CD4+ (<30%)	55	60.4	6	42.9	
(≥30%)	36	39.6	8	57.1	0.462
Viral load (<2.0$\log_{10}$)	20	21.5	6	40.0	
(≥2.0$\log_{10}$)	73	78.5	9	60.0	0.045

Odds of developing an anti-HBs response

An odds ratio (OR) analysis (Fig 4) indicated that being HIV-positive was associated with reduced odds of developing protective anti-HBs titres, based on titres of both ≥10 mIU/ml (OR 26.2, 95% CI 11.2-58.6) and ≥100 mIU/ml (OR 11.6, 95% CI 6.7-20.4). Younger age (<24 months) increased the odds of having an anti-HBs titre of ≥10 mIU/ml (OR 0.3, 95% CI 0.2-0.5) or ≥100 mIU/ml (OR 0.3, 95% CI 0.2-0.4). Among the HIV-positive subjects only, age <24 months only elevated the odds for developing an anti-HBs response of ≥100 mIU/ml (OR 0.1, 95% CI 0.06-0.4) (Fig 4B). Other characteristics analysed including gender, ART, CD4+ count, CD4+ ratio and HIV viral load were not found to be significantly predictive of anti-HBs titres at either threshold.

Modelling effects of interventions on HBV prevalence

We first fitted our transmission model (Fig 1) to demographic expectations for the age classes in the absence of transmission, using the expected population proportions published for South Africa as baseline (Fig S2, parameters detailed in Tables 2 and S2). With the posterior medians for the age parameters, we then fitted known HBV prevalence data derived from this cohort and from the published literature (Figure 1B/C, parameters detailed in Tables 2 and S3). Finally, using both the posterior medians for age and transmission parameters we simulated a multitude of scenarios involving vaccination and PMTCT interventions deployed first singly (Fig 1 D/E), and then in combination (Fig 5), quantifying 'impact' as reduction in total HBV prevalence (sum of acute and chronic carriers) in the post-vaccination era, and estimating time for prevalence to reach levels for which stochastic extinction would be highly likely.

ODE model solutions (Fig 1B) closely captured the pre-vaccination, target proportions of carriers (sum of I, C-, C+) recovered (HBcAb, R) and relative chronic prevalences of HBeAg+ (C+) and HBeAg− (C−) carriers, highlighting how the transmission model can mechanistically represent local HBV epidemiology in the absence of vaccination. The MCMC chains (Fig S3) and posteriors (Fig 1C) of fitted (unknown) parameters were also seen to have robust behaviours. Our Bayesian estimations propose that the rate of seroconversion (θ) from HBeAg+ to HBeAg- is extremely slow, with a median period of ≈ 18.5 yrs (95% CI ∈ [14, 22.2]), approximately 31% of the general population's lifespan and 37% of HBeAg+ lifespan (Table 2). Spontaneous clearance of chronic infection (ρ) was estimated to be even slower, close to 0.286% a year (95% CI ∈ [0.0349, 0.898]), capturing the yearly rate of 0.73% previously found in a Brazilian cohort (41). Hence, the model effectively suggests a life-time probability of around 0.11 of HBV clearance for individuals acquiring chronic infection very early in life. We note here that although we leave seroconversion (θ) from

HBeAg+ to HBeAg- free when fitting, its posterior with median of about 5.3% a year is compatible with empirical estimations (42) of yearly rates of < 2% for < 3 years of age and 4-5% for older children (43), with ≈ 90% of individuals acquiring HBV early in life remaining HBeAg+ at the ages of 15 − 20 years (44).

Fig 1D illustrates how increasing the proportion of infants given birth vaccination has a positive and progressive impact on reducing the population prevalence of HBV infection. Importantly, even with complete coverage of neonates, prevalence is shown to approach zero just under 400 years. These long time-scales are in keeping with an intervention that does not tackle the large established reservoir of chronic infection and targets only a small proportion of the population such that vaccine-induced herd-immunity accumulates slowly over several decades (Fig S6). For similar reasons, implementing robust PMTCT (Fig 1E) would also slowly reduce HBV prevalence, but since it does not prevent infection later but still early in life, PMTCT on its own would have a smaller overall impact than neonatal vaccination. Having illustrated the theoretical impact of these single interventions at a population level, we next used our model to explore the impact of combined interventions, considering vaccination of neonates together with older ages (Fig 5 panels ABCD-1), neonatal vaccination together with PMTCT (Fig 5 panels ABCD-2), and neonatal vaccination together with PMTCT plus 100% catch-up vaccination of all ages (Fig 5 panels ABCD-3).

Using the model, we investigated how different combinations of interventions would impact HBV epidemiology in terms of the time required to reduce total prevalence to 0.1% (Fig 5 panels A1-3). Combining immunization of neonates with older ages (>6 years) required the longest time (Fig 5 A1), with improvements seen when combining neonatal vaccination with PMTCT (Fig 5 A2), and shortest periods observed when combining the latter with a one off 100% catch-up of susceptible individuals (Fig 5 A3). In each of these scenarios, reaching 0.1% prevalence took >200 years, even under full coverage. However, total prevalence may be reduced to 1% (~8 times lower than the level of endemicity before interventions), on much shorter timescales (50 yrs) when neonatal vaccination and PMTCT are combined (Fig S10).

After 25 years, based on a current rate of ~75% vaccination coverage in neonates only (mean of estimated 56-97%), the model predicts a total reduction in prevalence of ~19% relative to the pre-vaccination era (Fig 5 B1-2). If coverage were to be maintained at a stable 95%, impact would be slightly higher with a reduction of 23% (Fig 5 B1-2). The addition of vaccination in older ages (>6 years old) was seen not to add much to this figure (Fig 5 B1). However, PMTCT was seen as highly beneficial, with a combination of 75% reduction in

vertical transmission and current neonate coverage achieving 30% reduction in total prevalence (Fig 5 B2). With both interventions being effective at 95%, prevalence could have been reduced by 35%. If vaccination of neonates and PMTCT at 95% had been coupled with an extra catch-up campaign to immunise 100% of the susceptible population, prevalence would be reduced by 43% (Fig 5 B3). The impact of catch-up vaccination was highest in the short and mid-term, but slowed down thereafter.

In considering the overall impact of any intervention, HBeAg+ individuals are the group with the highest public health importance as these present the highest risk of chronic liver disease, including cancer, and high risk of both horizontal and vertical transmission. We found that under current vaccination coverage of 75% of neonates, HBeAg+ carriers could be reduced by 41% in 25 years (Fig 5 D1-2); and, had coverage been 95%, a reduction up to 49% would have been possible. As observed for total prevalence, combining vaccination of neonates with older ages created minimal additional impact (Fig 5 D1). PMTCT, on the other hand, increased the impact of neonatal vaccination alone, with a reduction of 49% predicted for a combination of current 75% vaccination efforts and 50% reduction in vertical transmission. If both interventions had been maintained at 95%, the HBeAg+ carriers could have been reduced by a substantial 75% in only 25 years. As seen before for total prevalence, combining vaccination of neonates with PMCTC and a catchup of 100% would have generally increased impact (Fig 5 D3).

DISCUSSION

The work presented here is an important foundation for informing strategies that will move us towards the HBV targets enshrined within Sustainable Development Goals and Global Hepatitis Health Sector Strategy (2). With ambitious aims set out to be achieved by 2030, it is crucial that existing resources are deployed in the best possible way, based on a clear understanding of the likely scale and timeline for an impact to be evident at population level. While being optimistic about the improvements we can make in reducing population prevalence of HBV infection, a clear assessment of the challenge ahead is important advocacy for the development of new approaches, with the ultimate long-term aim still being HBV cure.

Studying a cohort of South African children demonstrates the potent effect of vaccination within individual communities: our observation that HBV infections are infrequent in these children (prevalence <1%) is in keeping with other studies that report a substantial decline in prevalence since universal infant HBV vaccination was introduced (25,45). A substantial proportion of HBV transmission in Africa is thought to arise before the age of 5 years (46)

and these results are therefore encouraging in demonstrating that vaccination – when deployed correctly - is indeed reducing HBV incidence in early childhood, when the risk of developing chronic infection is at its highest. Although previous studies in the region have indicated that HBV infection is not significantly associated with HIV status (22,24,47), our data do highlight a likely additional vulnerability of HIV-infected children based on lower antibody titres, and a rapid wane to below the threshold of anti-HBs <10 mIU/mL that is associated with protection.

HBV vaccination is given in South Africa at 6, 10, and 14 weeks; this provides a window of opportunity for perinatal HBV transmission (11,22). This is illustrated particularly by one subject within our cohort (KREC-151), an HIV-negative child with serologic evidence of past infection with HBV, despite documentation of the three-dose HBV vaccination schedule and anti-HBs titre of 201.8 mIU/ml. Perinatal transmission can be significantly reduced by the implementation of antenatal screening for HBV and the administration of a birth dose vaccine (48) supplemented with anti-HBV immunoglobulin, although this intervention may not be affordable in resource-limited settings (49). In the case of KREC-151, it seems most likely that vaccination occurred after infection with HBV had already been established. Systematic efforts to deliver the first vaccine dose soon after birth (in keeping with EPI recommendations) could reduce such transmission events, even in settings where HBV immune globin is not routinely available.

Vaccine-mediated immunity to HBV

Anti-HBs seroprevalence was significantly lower in HIV-positive participants when compared to HIV-negative subjects, irrespective of the threshold set for a protective titre. There are two possible explanations for this observation. First, impaired vaccine responses have previously been observed in HIV-positive individuals (25,50–53). However, given the lack of RTHB data for the HIV-positive study participants, we cannot exclude the second possibility, that coverage with the primary HBV vaccine course was lower among these children. This would be in keeping with a previous report that children born to HIV positive parents in South Africa are less likely to complete childhood vaccination programs (54).

Protective anti-HBs titres in HIV-positive subjects were significantly more frequent in subjects <24 months of age than in older subjects. This difference was not identified in the HIV-negative cohort and suggests that the vaccine responses in HIV-positive subjects wane rapidly after immunisation. This waning has been previously reported in both HIV-positive and HIV-negative subjects (40,45,50). However, loss of the anti-HBs response does not necessarily correlate with loss of clinical protection and anamnestic responses, where anti-

HBs titre is very low or absent but immunological memory remains, are thought to occur in a proportion of those vaccinated (55), although this memory may be attenuated in the context of HIV (56,57).

We found no difference in anti-HBs titres between participants on ART and those not on ART, although there are previous reports correlating ART with improved HBV vaccine responses (27,58). A previous study of Kimberley children demonstrated that recovery of CD4+ T cell percentage in HIV-positive children takes a median of five years after initiation of treatment (59); our current study is therefore likely to be underpowered to detect any true effect, given both the relatively short durations of ART treatment, and the small number of children not receiving ART. Interestingly, despite the lack of correlation between anti-HBs responses and treatment with ART, we did find that children with lower HIV viral loads had significantly higher anti-HBs titres, in keeping with previous studies (58,60). Based on current treatment guidelines, all HIV-infected children are now started on ART (61) and the immune reconstitution of this population over time should be anticipated to reduce the differences in vaccine responses between HIV-positive and HIV-negative groups.

HBV model projections

The model we have developed is statistically robust based on the population parameters we have included for this population, and we believe this is a novel and important tool for adding to our understanding about transmission dynamics and potential interventions for HBV, including offering the potential to scrutinise different strategies independently from one another. The determinants of an equilibrium in any population depend on a number of factors, which are determined by characteristics and behaviours of the host population (62) as well as potentially by the genetics of the virus. However, where the relevant epidemiological parameters have been defined, we believe the model could robustly be applied to other settings to explore the impact of interventions.

Based on the output from the model, we can demonstrate that targets for ‘eliminating viral hepatitis as a major public health threat by 2030’ are unlikely to be met, unless there is a major scaling up of both vaccination and PMTCT efforts. These two interventions implemented together, with a focus on neonatal vaccination, offer the best chances of making a significant impact on population prevalence. Perhaps more importantly, the predicted impact is greatest among HBeAg+ carriers, who are at an elevated risk of chronic liver disease and hepatocellular carcinoma, as well as being at higher risk of transmission, and therefore constitute the bulk of the public health burden of HBV.

The model suggests long time-lines, enumerated in centuries rather than decades, for possible elimination. Although our population data demonstrate a substantial reduction in prevalence of HBV infection in children under the age of five years, which is likely to rest almost entirely on the success of the EPI delivery of HBV vaccination, this intervention is tackling only a small fraction of the total population. As HBV is already endemic, is often clinically silent, and may persist in infected carriers for decades (possibly for a life-time), the time-scale for elimination is long. However, the results of our simulations underscore that we can have a major public health impact even without achieving elimination. Careful adjusting of expectations and aims, according to the scale on which particular changes occur, may inform the setting of realistic targets (e.g. reduction in the prevalence of HBeAg+ carriers could be a useful outcome measure when assessing the impact of interventions across a population). The wrong choice of target and timescale could result in unnecessary abandonment of a strategy that could have a major impact in a few decades.

In conclusion, for all simulated combinations of interventions, the model demonstrates that elimination can only occur over long time-scales. In the context of single interventions, we demonstrated that vaccination in neonates was the intervention resulting in highest impact, followed by PMCTC and vaccination in older ages (>6 years). When interventions were combined, the best approach was PMCTC with vaccination of neonates. A catch-up campaign was demonstrated to be beneficial, but our simulations suggest that for realistic catch-up coverages the added value would be minimal.

Our findings are consistent with those of another recent simulation of HBV prevention that also highlights the need for an amplification of current interventions if international sustainable development goals for HBV elimination are to be achieved (30). Our models concur in concluding that current vaccine-based interventions will reduce HBV prevalence by only about 40% over 35 years. However, there are also some important differences between the two studies. For instance, the previous study (30) approximates model behaviour to a wide range of epidemiological settings across many geographical regions, while we focus on a particular population for which we derive unknown epidemiological parameters. Our Bayesian framework therefore stands alone (e.g. as a tool) that can be applied to any population for which empirical support of key HBV epidemiological parameters is missing. Another important difference is that we focus our elimination analysis based on total prevalence of HBV, while the earlier study (30) used incidence or HBV-related deaths. Our study highlights the importance of considering reduction of HBV prevalence in evaluating the public health burden of HBV, an issue that has not received sufficient attention to date.

636 **Caveats and limitations**

637 There are a number of caveats that should be considered when analysing and interpreting
638 the clinical dataset. Different approaches to recruitment of HIV-positive and HIV-negative
639 children may introduce unintentional bias or confounders. Using respiratory admissions to
640 hospital for the KReC cohort provided us with an important opportunity to identify a sufficient
641 number of children quickly, and to acquire blood samples from children who would already
642 be undergoing venepuncture as part of their routine clinical care. However, this approach to
643 recruitment predominantly selected younger children (on average 9.4 months younger than
644 the HIV-positive cohort). This bias towards younger subjects in the HIV-negative group, gave
645 us less data with which to assess waning of the anti-HBs response among these children
646 with age. The KReC children may also be less healthy than a comparable group of HIV-
647 negative children in the community.
648
649 When designing the study, we elected to focus on children aged under age 60 months in
650 order to collect data from the RTHB which is not routinely carried by older children. In
651 practice, however, we did not capture good RTHB data from the HIV-positive group who
652 frequently did not bring this record to their clinic visits. Data collection from the RTHB is itself
653 subject to bias, as families who attend with such records may be those who are most likely
654 to have immunised their children, while those for whom data are missing could represent the
655 families in which children have missed vaccine doses. In this and other settings where
656 antenatal HBV screening is not routinely deployed (5,19,20), we deem it unlikely that there is
657 a significant difference in vaccination rates between infants born to HBV-positive versus
658 HBV-negative mothers. Numerous complex social factors are also relevant in determining
659 whether children are immunised; babies born to mothers who have HIV and/or HBV are
660 more likely to be in disadvantaged by poverty, and by illness and death in the family, such
661 that they might be less likely to present for (or respond to) vaccination.
662
663 We recognise that this is a small cohort of children, and that we may be underpowered to
664 detect associations between anti-HBs titre and other parameters (i.e. there is a risk of Type
665 II error). However, the convincing statistical associations between anti-HBs titre and both
666 HIV status and age demonstrate sufficient power to detect important signals. Furthermore,
667 we used cross-sectional data to investigate likely longitudinal patterns in anti-HBs titre
668 decline over time. The relatively small numbers in each age group and the lack of
669 longitudinal follow-up for individual children puts limitations on the interpretation of these
670 data, but the changes we observe here are consistent with reports from the existing literature
671 (40,63) and are compatible with a true biological phenomenon.
672

673 Our approach to screening for HBV infection in this population is limited by undertaking an
674 HBsAg assay. A more robust assessment, capturing cases of occult infection, would require
675 use of HBV DNA as a screening tool. In practice, this is too expensive for wide-spread
676 deployment and was not practical for this study on the same grounds. The lack of
677 understanding about the biological correlates of HBV-vaccine mediated immunity is another
678 challenge. On pragmatic grounds, we have presented data for anti-HBs thresholds of both
679 ≥10 mIU/ml and ≥100 mIU/ml. In the long-term, better understanding of the correlates of
680 protective immunity are required to tailor vaccine strategies to individuals or cohorts. Recent
681 data suggest that the site of immunization, diurnal timing of vaccine doses, and time of day
682 when samples are collected may also have significant impact on antibody titres (64),
683 although existing data for HBV vaccine do not support this (65). In this study, we did not set
684 out to capture these data, but they might be pertinent for future studies. We have also not
685 addressed issues such as maintenance of the cold-chain and vaccine storage which can
686 also influence efficacy. Finally, vaccine efficacy may be determined by the vaccine received;
687 the children immunised in this cohort would have received the traditional monovalent vaccine
688 (Biovac Paed), whereas children now being immunised in South Africa will have hexavalent
689 vaccination (HBV/DTP/IPV/Hib, Hexaxim, Sanofi-Pasteur).
690
691 Alternative approaches for HIV-positive subjects, such as supplementing the current
692 schedule with booster vaccinations and increased vaccine doses have been trialled with
693 variable results (60). A promising recent study of HIV-positive children found that repeating
694 the primary course of vaccination subsequent to response to ART generated lasting
695 protective immune responses (51). We recognise the potential significance of ART treatment
696 on HBV outcome in subjects with HIV/HBV coinfection, as first line ART regimens for this
697 population consistently include either lamivudine (3TC) or tenofovir (TDF), both of which
698 have activity against HBV. For all adults (including pregnant mothers) and adolescents, the
699 first line regimen is currently TDF, Emtricitabine (FTC) and Efavirenz (EFV) at diagnosis and
700 continuing for life (guidelines are available on-line at www.health.gov.za). In the case of
701 previous 3TC-based regimens, the potential for rapid selection of 3TC resistance in HBV
702 means it is not possible to assume a 3TC-based regimen will suppress HBV, as we and
703 others have previously identified (11)(66). In this specific cohort, we were unable to make a
704 robust assessment of the impact of ART as we did not set out to collect detailed prospective
705 ART treatment data, guidelines have changed numerous times since 2002 (and may also
706 have differed depending on age and timing of diagnosis), and lamivudine was intermittently
707 used as a substitute for nevirapine due to supply issues of the latter. Maternal TDF as part of
708 a specific PMTCT regimen was unlikely to have been delivered at the time of this study, as
709 antenatal HBV screening has not been routine practice to date (5). Together, these caveats

in our data clearly highlight the day-to-day challenges of drug provision and monitoring within this setting.

We present a parsimonious mathematical framework, not including, for instance, the proportion of the population infected with HIV, which may suffer from increased risk for vertical transmission and reduced vaccine efficacy. In the population studied here, ART has only been introduced in children achieving certain immunological criteria (as per old treatment guidelines), while in future, infected children will be started on treatment as soon as diagnosed (potentially at birth), which could be predicted to increase vaccine responses to similar levels as seen in the HIV-negative population; further studies will be required to assess this over time. More importantly, the effects of HIV and ART would be: (1) mostly in the absolute values of our projections, but not necessarily on the obtained differences in terms of impact between the simulated interventions; and (2) would be expected to make elimination more difficult, which would underscore our discussion points on goals for elimination. We also note that quantifications of time to elimination are problematic in a deterministic model such as ours, but our primary outcome is not to present a quantitative estimate for time to elimination, but rather to demonstrate that the predicted time scale is outside the proposed goals for 2030. We have not considered the influence of population migration on the success of interventions to eliminate HBV. Migration of non-immune and/or infected individuals into an area would delay the time to elimination estimated by our modeling approach. In the absence of clear data to underpin population migration in southern Africa, we have currently addressed our questions in the assumption that populations are static, but the potential impact on HBV control is an important consideration for regions in which there is significant population flux.

Conclusions

Our results are unique in presenting a detailed snapshot of the current situation, followed by a projection of future outcomes based on a mathematical model. We have affirmed the success of the HBV vaccine programme in reducing the prevalence of HBV in children, with current rates of <1% in the South African setting we have studied. This underlines the importance of ongoing immunisation, which is fundamental in preventing infection in the vulnerable early months of life. However, we also highlight that a small number of cases of HBV transmission continue, despite inclusion of the HBV vaccine in EPI, and that a proportion of children are potentially at risk of infection as a result of low anti-HBs titres, either as a result of incomplete immunisation, or because of poor antibody titres following vaccination (especially in the context of HIV infection). However, at a population level,

746 although neonatal immunisation is the best single intervention, our model demonstrates that
747 this alone does not offer a route to elimination. Substantial reduction of population
748 prevalence hinges on a combination of measures; the roles of catch-up vaccination and the
749 need for major efforts in PMTCT are highlighted by our model. A meaningful and sustainable
750 campaign to eliminate this infection also requires concerted efforts and investment in case
751 finding and treatment, education, reduction of stigma, and sexual and reproductive health
752 services. Ultimately, the only route to elimination of HBV may be to develop a cure.
753

754 **REFERENCES**

755

756 1. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.
757 2016;http://www.who.int/hepatitis/strategy2016-2021/ghs.
758 2. World Health Organization. Combating Hepatitis B and C to Reach Elimination by
759 2030: Advocacy Brief. 2016;http://apps.who.int/iris/bitstream/10665/206453/1/.
760 3. World Health Organization. Hepatitis B factsheet.
761 2017;http://www.who.int/mediacentre/factsheets/fs204/en.
762 4. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide
763 prevalence of chronic hepatitis B virus infection: A systematic review of data
764 published between 1965 and 2013. The Lancet. 2015;386:1546–55.
765 5. O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al.
766 Hepatitis B Virus as a Neglected Tropical Disease. PLOS Neglected Tropical
767 Diseases. 2017;11(10):https://doi.org/10.1371/journal.pntd.0005842.
768 6. Ott JJJ, Horn J, Krause G, Mikolajczyk RTT. Time trends of chronic HBV infection
769 over prior decades – A global analysis. Journal of Hepatology. 2017;66(April
770 2016):48–54.
771 7. Matthews PC, Beloukas A, Malik A, Carlson JM, Jooste P, Ogwu A, et al. Prevalence
772 and characteristics of hepatitis B virus (HBV) coinfection among HIV-Positive women
773 in South Africa and Botswana. PLoS ONE. 2015;10(7):e0134037.
774 8. Dibisceglie AM, Kew MC, Dusheiko GM, Berger EL, Song E, Paterson AC, et al.
775 Prevalence of hepatitis B virus infection among black children in Soweto. British
776 Medical Journal. 1986;292:1440–2.
777 9. Burnett RJJ, Francois G, Kew MCC, Leroux-Roels G, Meheus A, Hoosen AAA, et al.
778 Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan
779 Africa: a call for further investigation. Liver International. 2005;25(2):201–13.
780 10. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B
781 vaccination in South Africa. Vaccine. 2012;30(Supplement 3):C45–51.
782 11. Jooste P, van Zyl A, Adland E, Daniels S, Hattingh L, Brits A, et al. Screening,
783 characterisation and prevention of Hepatitis B virus (HBV) co-infection in HIV-positive
784 children in South Africa. Journal of Clinical Virology. 2016;85:71–4.
785 12. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and
786 effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis
787 Intervention Study (1986–90) and in the nationwide immunisation program. BMC
788 Infectious Diseases. 2014;14(7).
789 13. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K.
790 Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. The

American Journal of Medicine. 1992 Mar;92(3):254–6.

14. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, et al. Long-term persistence of anti-HBs after vaccination against HBV: An 18 year experience in health care workers. Vaccine. 2004;22:607–10.

15. Bialek SR, Bower W a, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. The Pediatric Infectious Disease Journal. 2008;27(10):881–5.

16. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. BMJ. 1997;314:1033–6.

17. World Health Organization. Preventing Perinatal Hepatitis B Virus Transmission : A Guide for Introducing and Strengthening Hepatitis B Birth Dose Vaccination. 2015;http://apps.who.int/iris/bitstream/10665/208278/1/.

18. Gentile I, Borgia G. Vertical transmission of hepatitis B virus: Challenges and solutions. International Journal of Women's Health. 2014;6(1):605–11.

19. Chotun N, Preiser W, van Rensburg CJ, Fernandez P, Theron GB, Glebe D, et al. Point-of-care screening for hepatitis B virus infection in pregnant women at an antenatal clinic : A South African experience. PLoS ONE. 2017;12(7):doi.org/10.1371/journal. pone.0181267 Editor:

20. Diale Q, Pattinson R, Chokoe R, Masenyetse L, Mayaphi S. Antenatal screening for hepatitis B virus in HIV-infected and uninfected pregnant women in the Tshwane district of South Africa. South African Medical Journal. 2015;106(1):97–100.

21. World Health Organization. Conference Report, Hepatitis B Vaccines: WHO Position Paper - Recommendations. Vaccine. 2010;28:589–90.

22. Chotun N, Nel E, Cotton MF, Preiser W, Andersson MI. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine. 2015;33(36):4618–22.

23. Statistics South Africa. Mid-year population estimates. 2016;https://www.statssa.gov.za/publications/P0302/P030.

24. Matthews PC, Geretti AM, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. Journal of Clinical Virology. 2014;61:20–33.

25. Beghin J-C, Ruelle J, Sokal E, Bachy A, Krishna M, Hall L, et al. Effectiveness of the South African Expanded Program of Immunization Against Hepatitis B in Children Infected With Human Immunodeficiency Virus-1 Living in a Resource-Limited Setting of Kwazulu-Natal. Journal of Medical Virology. 2017;89:182–5.

26. Siriaksorn S, Puthanakit T, Sirisanthana T, Sirisanthana V. Prevalence of protective

antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine. 2006;24(16):3095–9.

27. Pippi F, Bracciale L, Stolzuoli L, Giaccherini R, Montomoli E, Gentile C, et al. Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania. HIV Medicine. 2008;9(7):519–25.

28. Hashim A, Dang V, Bolotin S, Crowcroft NS. How and why researchers use the number needed to vaccinate to inform decision making-A systematic review. Vaccine. 2015;33(6):753–8.

29. Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population extensions of the NNV: Comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine. 2004;22(17–18):2192–8.

30. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. The Lancet Infectious Diseases. 2016;16(12):1399–408.

31. Sharp CP, Gregory WF, Hattingh L, Malik A, Adland E, Daniels S, et al. PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort. Wellcome Open Research. 2017;2(0):26.

32. Public Health England. Hepatitis B. In: Green Book: Immunisation against infectious disease. 2016. p. 161–85.

33. Jack A, Hall A, Maine N, Mendy M, Whittle H. What level of hepatitis B antibody is protective? The Journal of Infectious Diseases. 1999;179:489–92.

34. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg dean F, et al. Long-term Immunogenicity and Efficacy of Hepatitis B Vaccine in Homosexual Men. New England Journal of Medicine. 1986;315(4):209–14.

35. Hidalgo B, Goodman M. Multivariate or multivariable regression? American Journal of Public Health. 2013;103(1):39–40.

36. Liang TJ. Hepatitis B: The virus and Disease. Hepatology. 2009;49:doi:10.1002/hep.22881.

37. World Health Organization. World Health Organization Hepatitis B Factsheet. 2017;http://www.who.int/mediacentre/factsheets/fs204/en.

38. Chen HL, Lin LH, Hu FC, Lee J Te, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142(4):773–81.

39. Bui TTT, Tran TT, Nghiem MN, Rahman P, Tran TTT, Dinh MNH, et al. Molecular characterization of hepatitis B virus in Vietnam. BMC Infectious Diseases. 2017;17(601):DOI 10.1186/s12879-017-2697-x.

865 40. Chaouch H, Hachfi W, Fodha I, Kallala O, Saadi S, Bousaadia A, et al. Impact and
866 long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B
867 vaccination in Tunisia. Epidemiology and Infection. 2016;144(16):3365–75.
868 41. Ferreira SC, Chacha SG, Souza FF, Teixeira AC, Santana RC, Villanova MG, et al.
869 Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients
870 followed at a university hospital. Ann Hepatol. 2014;13(6):762–70.
871 42. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic
872 hepatitis B. Hepatology International. 2009;3(3):425–33.
873 43. Chang M, Hsu H, Hsu H, Ni Y, Chen D. The Significance of Spontaneous Hepatitis B
874 e Antigen Seroconversion in Childhood□: With Special Emphasis on the Clearance of
875 Hepatitis B e Antigen Before 3 Years of Age.
876 44. Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus
877 infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431
878 asymptomatic Chinese HBsAg carriers. Clinical infectious diseases. 1993;16(5):709–
879 13.
880 45. Amponsah-dacosta E, Lebelo RL, Rakgole JN, Burnett RJ, Selabe SG, Mphahlele
881 MJ. Evidence for a Change in the Epidemiology of Hepatitis B Virus Infection After
882 Nearly Two Decades of Universal Hepatitis B Vaccination in South Africa. Journal of
883 Medical Virology. 2014;924:918–24.
884 46. Healy S a, Gupta S, Melvin AJ. HIV/HBV coinfection in children and antiviral therapy.
885 Expert review of anti-infective therapy. 2013;11(3):251–63.
886 47. Andersson MI, Maponga TG, Ijaz S, Barnes J, Theron GB, Meredith SA, et al. The
887 epidemiology of hepatitis B virus infection in HIV-infected and HIV-uninfected
888 pregnant women in the Western Cape, South Africa. Vaccine. 2013;31(47):5579–84.
889 48. Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional
890 birth dose of Hepatitis B vaccine to prevent perinatal transmission in a medical setting
891 in Mozambique. Vaccine. 2012;31:252–9.
892 49. Lee C, Gong Y, Brok J, Boxall EH, Gluud C, Eh B, et al. Hepatitis B immunisation for
893 newborn infants of hepatitis B surface antigen-positive mothers (Review). Cochrane
894 Database of Systematic Reviews. 2006;(2):CD004790.
895 50. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of
896 chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: Consensus of
897 an expert panel on behalf of the European Society of Pediatric Gastroenterology,
898 Hepatology and Nutrition. Journal of Hepatology. 2013;59(4):814–29.
899 51. Lao-araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana
900 V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in
901 HIV-infected children on antiretroviral therapy. Vaccine. 2011;29(23):3977–81.

902 52. Büchner A, Omar FE, Vermeulen J, Reynders DT. Investigating hepatitis B immunity
903 in patients presenting to a Paediatric Haematology and oncology unit in South Africa.
904 South African Medical Journal. 2014;104(9):628–31.
905 53. Mayaphi SH, Rossouw TM, Masemola DP, Olorunju S a S, Mphahlele MJ, Martin DJ.
906 HBV/HIV co-infection : The dynamics of HBV in South African patients with AIDS.
907 South African Medical Journal. 2012;102(3):157–62.
908 54. Ndirangu J, Barnighausen T, Tanser F, Tint K, Newell ML, Bärnighausen T, et al.
909 Levels of childhood vaccination coverage and the impact of maternal HIV status on
910 child vaccination status in rural KwaZulu-Natal, South Africa. Tropical Medicine and
911 International Health. 2009;14(11):1383–93.
912 55. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: The
913 role of vaccine immunogenicity in immune memory. Vaccine. 2000;19(7–8):877–85.
914 56. Lao-araya M, Puthanakit T, Aurpibul L, Sirisanthana T, Sirisanthana V. Antibody
915 response to hepatitis B re-vaccination in HIV-infected children with immune recovery
916 on highly active antiretroviral therapy. Vaccine. 2007;25(29):5324–9.
917 57. Abzug MJ, Warshaw MG, Rosenblatt HM, Levin MJ, Nachman S, Pelton SI, et al.
918 Immunogenicity and immunologic memory after hepatitis B virus booster vaccination
919 in HIV-infected children receiving highly active antiretroviral therapy. The Journal of
920 Infectious Diseases. 2009;200(6):935–46.
921 58. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical
922 predictors of impaired response to hepatitis B vaccination in HIV-infected persons.
923 International journal of STD & AIDS. 2008;19(9):600–4.
924 59. Mori M, Adland E, Paioni P, Swordy A, Mori L, Laker L, et al. Sex Differences in
925 Antiretroviral Therapy Initiation in Pediatric HIV Infection. PloS one.
926 2015;10(7):e0131591.
927 60. Catherine F-X, Piroth L. Hepatitis B virus vaccination in HIV-infected people: a review.
928 Human Vaccines & Immunotherapeutics. 2017;DOI:
929 10.1080/21645515.2016.1277844.
930 61. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs
931 for treating and preventing HIV infection: recommendations for a public health
932 approach. World Health Organization.
933 2016;http://apps.who.int/iris/bitstream/10665/208825/1/.
934 62. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. Hepatitis-B virus endemicity:
935 heterogeneity, catastrophic dynamics and control. Nature Medicine. 2001;7(5):619–
936 24.
937 63. Katoonizadeh A, Sharafkhah M, Ostovaneh MR, Norouzi A, Khoshbakht N,
938 Mohamadkhani A, et al. Immune responses to hepatitis B immunization 10-18 years

after primary vaccination: a population-based cohort study. Journal of Viral Hepatitis. 2016;23:805–11.

64. Kurupati RK, Kossenkoff A, Kannan S, Haut LH, Doyle S, Yin X, et al. The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. Vaccine. 2017;35(30):3700–8.

65. Karabay O, Temel A, Koker AG, Tokel M, Ceyhan M, Kocoglu E. Influence of circadian rhythm on the efficacy of the hepatitis B vaccination. Vol. 26, Vaccine. Netherlands; 2008. p. 1143–4.

66. Wandeler G, Musukuma K, Zürcher S, Vinikoor MJ, Llenas-García J, Aly MM, et al. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. PLOS one. 2016;11(3):doi:10.1371/journal. pone.152043.

FIGURE LEGENDS

Figure 1. Diagram of HBV transmission model, statistical fitting and predicted impact of single interventions.

A: HBV transmission model, showing population groups who are susceptible (divided into infants (S_i), children (S_c) and older ages (S_a)), chronically infected (divided into HBeAg+ (C+) and HBeAg- (C-)), acutely infected (I), recovered (R) and vaccinated (V), and the transitions (Table 2) between these groups. Full details of the model are available in Supplementary Data File 2, and a summary in the Methods section of the main text. B: Distributions of pre-vaccination ODE model output at equilibrium for the fitted classes: expected proportion of acute infections (I, yellow), proportion recovered (R, green), relative proportions of C+ and C- (purple, red, respectively). Dashed vertical lines present the target proportions to be fitted based on the SA cohort and literature reports (values in Tables S2 and S3). C: MCMC posterior distributions obtained by the Bayesian approach for unknown parameters (marked fitted in Table 2). D: Dynamics of total HBV prevalence based on vaccination of newborns (starting at t=0), with proportion vaccinated designated as δn (where δn=1 is equivalent to an intervention that covers 100% of newborns). E: Dynamics of total HBV prevalence, based on implementing an intervention that prevents mother to child transmission (PMTCT, starting at t=0) by a proportion represented by parameter ζ (ζ=1 is equivalent to averting 100% of possible transmission events). Fitted parameters as described in the Results section and all others as in Table 2.

Figure 2: Hepatitis B surface antibody (anti-HBs) titres mediated by vaccination in HIV-positive (HIV+) and HIV-negative (HIV-) children aged 6-60 months in Kimberley, South Africa.

A: Scatter plot representing vaccine-mediated antibody titres, indicating median and interquartile ranges, for HIV-positive and HIV-negative children (p-value by Mann Whitney U test). B: Proportion of HIV-positive and HIV-negative children with anti-HBs ≥10 mIU/ml (p-value by Fisher's Exact Test). C: Proportion of HIV-positive and HIV-negative children with anti-HBs ≥100 mIU/ml (p-value by Fisher's Exact Test).

Figure 3: Relationship between age and vaccine-mediated Hepatitis B surface antibody (anti-HBs) titres in HIV-positive and HIV-negative children in Kimberley, South Africa.

Ages of children attaining anti-HBs titres ≥100 mIU/ml for HIV-positive (A) and HIV-negative children (B) age 6-60 months. Median ages, interquartile ranges and p-values by Mann-Whitney U test are indicated. C, D: Relationship between age and vaccine-mediated Ab titre among HIV-positive children including those age 6-60 months and an older cohort age >60 months (range 64-193 months; see Table 4). P-value by Mann Whitney U test (panel C) and by Spearman's rank correlation test (panel D). E: Anti-HBs titre for HIV-positive and HIV-negative children according to age. Each point represents the mean titre for the group of children aged ≤12 months (1 yr), 13-24 months (2 yrs), 25-36 months (3 yrs), 37-48 months (4 yrs), 49-60 months (5 years).

Figure 4. Odds ratios for protective response to HBV vaccination in children age 6-60 months in Kimberley, South Africa.

Odds ratios are shown for anti-HBs titre <10mIU/ml and <100mIU/ml in the whole cohort (grey) and in HIV-positive children (black). Statistically significant OR are denoted * and significant p-values are indicated in bold.

Figure 5. Impact of combined interventions on HBV prevalence and time to elimination.

A1-3: time to elimination of HBV based on a threshold of 1 carrier per 1000 individuals in the population. B1-3: Reduction of total HBV prevalence for 25 years after the start of interventions. C1-3: Reduction of total HBV prevalence for 50 years after the start of interventions. D1-3: Reduction in HBeAg+ carriers (model class 'C+') for 25 years after the start of interventions. A/B/C/D: In all cases, the x-axis shows the proportion of neonates vaccinated. Top row: neonatal vaccination combined with routine vaccination at older ages (>6 years old, y-axis). Middle row: neonatal vaccination combined with reduction in vertical transmission (PMTCT, y-axis). Bottom row: neonatal vaccination combined with reduction in vertical transmission (PMTCT, y-axis) after a catch-up campaign covering 100% of the

susceptible population. Dashed lines are visual references for 70%, 80% and 90% of the respective interventions. Parameters as in Table S1 of supplementary data file 2.

SUPPLEMENTARY DATA LEGENDS

Suppl data 1. Metadata for three paediatric cohorts recruited in Kimberley, South Africa, including longitudinal CD4+ T cell and viral load data for paediatric HIV cohort age ≤60 months in Kimberley, South Africa.

Suppl data 2. Variables used to inform a population-based model of HBV transmission and prevention, with supporting references and a complete methods description for model of HBV transmission and prevention.

ACKNOWLEDGEMENTS

Nil

CONFLICTS OF INTEREST

None to declare

FUNDING

PCM, PK and PJRG are funded by the Wellcome Trust (grant numbers 110110/Z/15/Z to PM, 109965MA to PK, and 104748MA to PJRG); https://wellcome.ac.uk. Recruitment and serological testing of the KReC cohort was covered by a project grant awarded to PCM from the Rosetrees Trust http://www.rosetreestrust.co.uk/. SG and JL received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 268904-DIVERSITY https://erc.europa.eu/. PK is also funded by an NIHR Senior Fellowship https://www.nihr.ac.uk/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


A
Z'
Z
μ
S_i
λ(1-ψ)
c
λψ
aVa
Z'
V
μ
W
C^+
μ
S_c
I
μ
μ_p
λ(1-ε)
λε
θ
λ(1-γ)
a(1-Va)
aVa
λγ
σ
μ
C^-
μ
S_a
R
ρ


Fitted known model classes: solutions vs literature
B
frequency
proportion of population in class
acute infected (I)
recovered, HBcAb+ (R)
prop. chronic HBeAg+ (C+)
prop. chronic HBeAg− (C−)
literature values


Fitted unknown parameters: solutions
C
frequency
parameter value
beta
theta
rho


Projection: Impact of neonate vaccination
D
HBV prevalence
years after intervention start
δn


Projection: Impact of PMTCT
E
HBV prevalence
years after intervention start
ζ


A
P<0.0001
Anti-HBs titre (mIU/ml)
1000
900
800
700
600
500
400
300
200
100
0
HIV +
HIV -
n = 136
Median titre
11.1 mIU/ml
n = 174
Median titre
196.1 mIU/ml
B
P<0.0001
Proportion of cohort (%)
100
50
0
HIV+
HIV-
C
P<0.0001
Proportion of cohort (%)
100
50
0
HIV+
HIV-
Vaccine response
No vaccine response


A
HIV+
P=0.0008
Age (months)
0
20
40
60
<100
≥100
Anti-HBs titre (mIU/ml)
n=113
Median age
31 months
n=23
Median age
17 months
B
HIV-
ns
Age (months)
0
20
40
60
<100
≥100
Anti-HBs titre (mIU/ml)
n=56
Median age
19 months
n=119
Median age
17 months
C
HIV+
P<0.0001
Anti-HBs titre (mIU/ml)
0
500
1000
≤60 months
>60 months
Age (months)
n=136
Median titre
11.1 mIU/ml
n=93
Median titre
<10 mIU/ml
D
HIV+
Anti-HBs titre (mIU/ml)
0
500
1000
20
40
60
Age (months)
n=136
R2= 0.06
P=0.004
E
HIV+
HIV-
Average anti-HBs titre (mIU/ml)
0
100
200
300
400
500
12
24
36
48
60
Age (months)


A
P value
HIV VL <2.0 log10
0.07
CD4+ ratio <30%
0.7
CD4+ count <1000
0.3
On ART
0.8
Age <24 months
0.07
Sex (male)
0.9
Age <24 months*
<0.0001
Sex(male)
0.5
HIV positive*
<0.0001
Characteristic
0.01
0.1
1
10
100
Odds ratio of HBsAb <10
B
P value
HIV VL <2.0 log10
0.2
CD4+ ratio <30%
0.3
CD4+ count <1000
0.8
On ART
0.6
Age <24 months*
0.0001
Sex (male)
0.2
Age <24 months*
<0.0001
Sex (male)
>0.9999
HIV positive*
<0.0001
Characteristic
0.01
0.1
1
10
100
Odds ratio of HBsAb <100
HIV-positive subjects = 60 months
All subjects = 60 months


YEARS FOR HBV PREVALENCE
TO REACH 1 IN 1000 INDIVIDUALS
IN POST-VACCINATION ERA
REDUCTION IN HBV PREVALENCE
RELATIVE TO PRE-VACCINATION ERA
after 25 years
after 50 years
REDUCTION IN HBeAg+ PREVALENCE
RELATIVE TO PRE-VACCINATION ERA
after 25 years
vaccination coverage
OLDER AGES
PMTCT
PMTCT ⊕
100% catch-up
vaccination coverage
NEONATES
A1
A2
A3
B1
B2
B3
C1
C2
C3
D1
D2
D3
450
400
350
300
250
200
0%
25%
50%
75%
100%
0.2
0.4
0.6
0.8